Literature DB >> 19724060

Tumor suppression by LKB1: SIK-ness prevents metastasis.

Reuben J Shaw1.   

Abstract

The LKB1 serine-threonine kinase is a tumor suppressor that is inactivated in a large number of sporadic human lung non-small cell carcinomas (NSCLCs) and cervical cancers. Genetic deletion of LKB1 in various mouse tissues results in tumorigenesis, and loss of LKB1 increases metastasis in a mouse model of NSCLC. LKB1 directly activates a family of 14 kinases related to AMPK [adenosine monophosphate (AMP)-activated protein kinase] to control cell metabolism, growth, and polarity, though which of these are critical to its tumor suppressor functions remain undefined. The LKB1-dependent kinase SIK1 (salt-inducible kinase 1) has now been identified as a key modulator of anoikis (apoptosis induced by cell detachment) and transformation in culture, and its modulation of the tumor suppressor p53 controls metastasis in transplanted tumor cells. Reduced SIK1 expression is correlated with poor prognosis in two large human breast cancer data sets. These findings suggest that SIK1 is a key upstream regulator of p53-dependent anoikis that may be targeted in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19724060     DOI: 10.1126/scisignal.286pe55

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  15 in total

Review 1.  Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Authors:  Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

2.  Integrative Analysis of Normal Long Intergenic Non-Coding RNAs in Prostate Cancer.

Authors:  Pushpinder Bawa; Sajna Zackaria; Mohit Verma; Saurabh Gupta; R Srivatsan; Bibha Chaudhary; Subhashini Srinivasan
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

3.  Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients.

Authors:  Yanqi He; Yalun Li; Zhixin Qiu; Bin Zhou; Shaoqin Shi; Kui Zhang; Yangkun Luo; Qian Huang; Weimin Li
Journal:  Mol Cancer       Date:  2014-01-31       Impact factor: 27.401

4.  Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells.

Authors:  Chun-Hao Tsai; Hsiao-Chi Tsai; Ho-Ning Huang; Chih-Hung Hung; Chin-Jung Hsu; Yi-Chin Fong; Horng-Chaung Hsu; Yuan-Li Huang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2015-01-01

5.  Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis.

Authors:  Chao Qu; Yaqin Qu
Journal:  Oncotarget       Date:  2017-01-10

6.  Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma.

Authors:  Elena Pomari; Federica Lovisa; Elisa Carraro; Simona Primerano; Emanuele S G D'Amore; Paolo Bonvini; Luca Lo Nigro; Rita De Vito; Luciana Vinti; Piero Farruggia; Marta Pillon; Giuseppe Basso; Katia Basso; Lara Mussolin
Journal:  Oncotarget       Date:  2017-11-11

7.  Endothelin-1 promotes epithelial-mesenchymal transition in human chondrosarcoma cells by repressing miR-300.

Authors:  Min-Huan Wu; Pei-Han Huang; Mingli Hsieh; Chun-Hao Tsai; Hsien-Te Chen; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2016-10-25

8.  Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers.

Authors:  Shicai Fan; Jianxiong Tang; Nan Li; Ying Zhao; Rizi Ai; Kai Zhang; Mengchi Wang; Wei Du; Wei Wang
Journal:  NPJ Genom Med       Date:  2019-02-01       Impact factor: 8.617

9.  IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways.

Authors:  István Gyurján; Sandra Rosskopf; Johana A Luna Coronell; Daniela Muhr; Christian Singer; Andreas Weinhäusel
Journal:  Oncotarget       Date:  2019-05-28

10.  Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer.

Authors:  T Komiya; A Coxon; Y Park; W-D Chen; M Zajac-Kaye; P Meltzer; T Karpova; F J Kaye
Journal:  Oncogene       Date:  2009-12-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.